Investment Summary

Ampersand Capital Partners Invests In Genezen

On January 5, 2021, growth capital firm Ampersand Capital Partners invested in life science company Genezen

Investment Highlights
  • This is Ampersand Capital Partners’ 26th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 53rd transaction in the United States.
  • This is Ampersand Capital Partners’ 2nd transaction in Indiana.

Investment Summary
Date 2021-01-05
Target Genezen
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type Growth Capital

Target

Genezen

Indianapolis, Indiana, United States
Genezen is a cell and gene therapy contract development and manufacturing organization (CDMO) focused on early-phase process development, vector production, and analytical testing services. Genezen was founded in 2014 and is based in Indianapolis, Indiana.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 57 of 84
Sector (Life Science) 26 of 43
Type (Growth Capital) 16 of 24
State (Indiana) 2 of 2
Country (United States) 53 of 69
Year (2021) 1 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-21 ALPCO

Salem, New Hampshire, United States

ALPCO is an importer and distributor of immunoassay-based products for the North American life science markets. ALPCO is a provider of proprietary and distributed diagnostics solutions, with over 60 collaborating partners from around the globe. ALPCO was founded in 1990 and is based in Salem, New Hampshire.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-01 Recipharm

Stockholm, Sweden

Recipharm is a global Pharma CDMO providing a full-service offering to leading Pharmaceutical companies and Biotechs globally. Recipharm was founded in 1995 and is based in Stockholm, Sweden.

Buy -
Mergr

Product

Company

Legal